nodes	percent_of_prediction	percent_of_DWPC	metapath
Indacaterol—UGT1A1—Etoposide—urinary bladder cancer	0.201	0.282	CbGbCtD
Indacaterol—ABCB1—Mitomycin—urinary bladder cancer	0.194	0.272	CbGbCtD
Indacaterol—CYP3A4—Thiotepa—urinary bladder cancer	0.088	0.124	CbGbCtD
Indacaterol—ABCB1—Gemcitabine—urinary bladder cancer	0.0558	0.0783	CbGbCtD
Indacaterol—ABCB1—Cisplatin—urinary bladder cancer	0.0405	0.0569	CbGbCtD
Indacaterol—ABCB1—Etoposide—urinary bladder cancer	0.0398	0.0559	CbGbCtD
Indacaterol—ABCB1—Doxorubicin—urinary bladder cancer	0.0272	0.0381	CbGbCtD
Indacaterol—ABCB1—Methotrexate—urinary bladder cancer	0.0263	0.0369	CbGbCtD
Indacaterol—CYP3A4—Etoposide—urinary bladder cancer	0.0238	0.0335	CbGbCtD
Indacaterol—CYP3A4—Doxorubicin—urinary bladder cancer	0.0163	0.0228	CbGbCtD
Indacaterol—UGT1A1—urine—urinary bladder cancer	0.0104	0.348	CbGeAlD
Indacaterol—UGT1A1—prostate gland—urinary bladder cancer	0.00373	0.125	CbGeAlD
Indacaterol—CYP3A4—urine—urinary bladder cancer	0.00333	0.112	CbGeAlD
Indacaterol—UGT1A1—renal system—urinary bladder cancer	0.00254	0.0852	CbGeAlD
Indacaterol—ADRB1—prostate gland—urinary bladder cancer	0.00253	0.0846	CbGeAlD
Indacaterol—Dermatitis—Valrubicin—urinary bladder cancer	0.00138	0.0079	CcSEcCtD
Indacaterol—ADRB1—female reproductive system—urinary bladder cancer	0.00138	0.0462	CbGeAlD
Indacaterol—Headache—Valrubicin—urinary bladder cancer	0.00137	0.00785	CcSEcCtD
Indacaterol—Dyspnoea—Mitomycin—urinary bladder cancer	0.00135	0.0077	CcSEcCtD
Indacaterol—Nausea—Valrubicin—urinary bladder cancer	0.0013	0.00745	CcSEcCtD
Indacaterol—Hyperglycaemia—Thiotepa—urinary bladder cancer	0.0012	0.00689	CcSEcCtD
Indacaterol—Pneumonia—Thiotepa—urinary bladder cancer	0.0012	0.00685	CcSEcCtD
Indacaterol—Infestation—Thiotepa—urinary bladder cancer	0.00119	0.00681	CcSEcCtD
Indacaterol—Infestation NOS—Thiotepa—urinary bladder cancer	0.00119	0.00681	CcSEcCtD
Indacaterol—Hypokalaemia—Gemcitabine—urinary bladder cancer	0.00118	0.00677	CcSEcCtD
Indacaterol—Nasopharyngitis—Fluorouracil—urinary bladder cancer	0.00114	0.00654	CcSEcCtD
Indacaterol—Bronchospasm—Gemcitabine—urinary bladder cancer	0.00111	0.00632	CcSEcCtD
Indacaterol—Hypokalaemia—Cisplatin—urinary bladder cancer	0.0011	0.00631	CcSEcCtD
Indacaterol—Nasopharyngitis—Cisplatin—urinary bladder cancer	0.00108	0.0062	CcSEcCtD
Indacaterol—Angina pectoris—Fluorouracil—urinary bladder cancer	0.00108	0.00615	CcSEcCtD
Indacaterol—Connective tissue disorder—Thiotepa—urinary bladder cancer	0.00105	0.00601	CcSEcCtD
Indacaterol—Upper respiratory tract infection—Fluorouracil—urinary bladder cancer	0.00103	0.00587	CcSEcCtD
Indacaterol—Hyperglycaemia—Gemcitabine—urinary bladder cancer	0.00101	0.0058	CcSEcCtD
Indacaterol—Pneumonia—Gemcitabine—urinary bladder cancer	0.00101	0.00576	CcSEcCtD
Indacaterol—Dizziness—Mitomycin—urinary bladder cancer	0.000999	0.00571	CcSEcCtD
Indacaterol—Cardiac disorder—Thiotepa—urinary bladder cancer	0.000992	0.00567	CcSEcCtD
Indacaterol—Pneumonia—Fluorouracil—urinary bladder cancer	0.000991	0.00567	CcSEcCtD
Indacaterol—Infestation NOS—Fluorouracil—urinary bladder cancer	0.000985	0.00563	CcSEcCtD
Indacaterol—Infestation—Fluorouracil—urinary bladder cancer	0.000985	0.00563	CcSEcCtD
Indacaterol—Immune system disorder—Thiotepa—urinary bladder cancer	0.000966	0.00552	CcSEcCtD
Indacaterol—Mediastinal disorder—Thiotepa—urinary bladder cancer	0.000964	0.00551	CcSEcCtD
Indacaterol—Rash—Mitomycin—urinary bladder cancer	0.000952	0.00545	CcSEcCtD
Indacaterol—Dermatitis—Mitomycin—urinary bladder cancer	0.000951	0.00544	CcSEcCtD
Indacaterol—Headache—Mitomycin—urinary bladder cancer	0.000946	0.00541	CcSEcCtD
Indacaterol—Bronchospasm—Etoposide—urinary bladder cancer	0.000944	0.0054	CcSEcCtD
Indacaterol—Malnutrition—Thiotepa—urinary bladder cancer	0.000931	0.00532	CcSEcCtD
Indacaterol—Sinusitis—Fluorouracil—urinary bladder cancer	0.000924	0.00528	CcSEcCtD
Indacaterol—UGT1A1—Biological oxidations—NAT1—urinary bladder cancer	0.000909	0.0109	CbGpPWpGaD
Indacaterol—CYP3A4—Aflatoxin B1 metabolism—GSTM1—urinary bladder cancer	0.000901	0.0108	CbGpPWpGaD
Indacaterol—Nausea—Mitomycin—urinary bladder cancer	0.000897	0.00513	CcSEcCtD
Indacaterol—UGT1A1—Metapathway biotransformation—GSTO2—urinary bladder cancer	0.000897	0.0108	CbGpPWpGaD
Indacaterol—Oedema peripheral—Gemcitabine—urinary bladder cancer	0.000886	0.00507	CcSEcCtD
Indacaterol—Connective tissue disorder—Gemcitabine—urinary bladder cancer	0.000884	0.00505	CcSEcCtD
Indacaterol—Musculoskeletal pain—Epirubicin—urinary bladder cancer	0.000868	0.00496	CcSEcCtD
Indacaterol—Pneumonia—Etoposide—urinary bladder cancer	0.00086	0.00492	CcSEcCtD
Indacaterol—Anaemia—Thiotepa—urinary bladder cancer	0.00086	0.00492	CcSEcCtD
Indacaterol—Infestation—Etoposide—urinary bladder cancer	0.000856	0.00489	CcSEcCtD
Indacaterol—Infestation NOS—Etoposide—urinary bladder cancer	0.000856	0.00489	CcSEcCtD
Indacaterol—UGT1A1—Phase II conjugation—NAT2—urinary bladder cancer	0.000852	0.0102	CbGpPWpGaD
Indacaterol—ABCB1—prostate gland—urinary bladder cancer	0.000846	0.0284	CbGeAlD
Indacaterol—Cardiac disorder—Gemcitabine—urinary bladder cancer	0.000835	0.00477	CcSEcCtD
Indacaterol—UGT1A1—Biological oxidations—UGT2B7—urinary bladder cancer	0.000832	0.00999	CbGpPWpGaD
Indacaterol—Connective tissue disorder—Cisplatin—urinary bladder cancer	0.000824	0.00471	CcSEcCtD
Indacaterol—UGT1A1—Metapathway biotransformation—UGT2B7—urinary bladder cancer	0.00082	0.00985	CbGpPWpGaD
Indacaterol—CYP3A4—renal system—urinary bladder cancer	0.000814	0.0273	CbGeAlD
Indacaterol—Immune system disorder—Gemcitabine—urinary bladder cancer	0.000812	0.00465	CcSEcCtD
Indacaterol—Cough—Thiotepa—urinary bladder cancer	0.000812	0.00464	CcSEcCtD
Indacaterol—Mediastinal disorder—Gemcitabine—urinary bladder cancer	0.000811	0.00463	CcSEcCtD
Indacaterol—Musculoskeletal pain—Doxorubicin—urinary bladder cancer	0.000803	0.00459	CcSEcCtD
Indacaterol—Myalgia—Thiotepa—urinary bladder cancer	0.000792	0.00453	CcSEcCtD
Indacaterol—Unspecified disorder of skin and subcutaneous tissue—Thiotepa—urinary bladder cancer	0.000787	0.0045	CcSEcCtD
Indacaterol—Cardiac disorder—Cisplatin—urinary bladder cancer	0.000778	0.00445	CcSEcCtD
Indacaterol—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP4B1—urinary bladder cancer	0.000774	0.0093	CbGpPWpGaD
Indacaterol—Diabetes mellitus—Methotrexate—urinary bladder cancer	0.000764	0.00437	CcSEcCtD
Indacaterol—Immune system disorder—Cisplatin—urinary bladder cancer	0.000757	0.00433	CcSEcCtD
Indacaterol—Mediastinal disorder—Cisplatin—urinary bladder cancer	0.000756	0.00432	CcSEcCtD
Indacaterol—Infection—Thiotepa—urinary bladder cancer	0.000755	0.00431	CcSEcCtD
Indacaterol—UGT1A1—Biological oxidations—CYP4B1—urinary bladder cancer	0.000749	0.009	CbGpPWpGaD
Indacaterol—Nervous system disorder—Thiotepa—urinary bladder cancer	0.000745	0.00426	CcSEcCtD
Indacaterol—Tachycardia—Thiotepa—urinary bladder cancer	0.000741	0.00424	CcSEcCtD
Indacaterol—UGT1A1—Metapathway biotransformation—CYP4B1—urinary bladder cancer	0.000738	0.00887	CbGpPWpGaD
Indacaterol—Skin disorder—Thiotepa—urinary bladder cancer	0.000738	0.00422	CcSEcCtD
Indacaterol—Malnutrition—Cisplatin—urinary bladder cancer	0.00073	0.00417	CcSEcCtD
Indacaterol—Anaemia—Gemcitabine—urinary bladder cancer	0.000724	0.00414	CcSEcCtD
Indacaterol—ABCB1—seminal vesicle—urinary bladder cancer	0.000715	0.024	CbGeAlD
Indacaterol—Diabetes mellitus—Epirubicin—urinary bladder cancer	0.000715	0.00409	CcSEcCtD
Indacaterol—Cardiac disorder—Etoposide—urinary bladder cancer	0.000713	0.00408	CcSEcCtD
Indacaterol—Anaemia—Fluorouracil—urinary bladder cancer	0.000711	0.00407	CcSEcCtD
Indacaterol—Muscle spasms—Cisplatin—urinary bladder cancer	0.000702	0.00401	CcSEcCtD
Indacaterol—Immune system disorder—Etoposide—urinary bladder cancer	0.000694	0.00397	CcSEcCtD
Indacaterol—Mediastinal disorder—Etoposide—urinary bladder cancer	0.000692	0.00396	CcSEcCtD
Indacaterol—Musculoskeletal discomfort—Thiotepa—urinary bladder cancer	0.000692	0.00396	CcSEcCtD
Indacaterol—Tremor—Cisplatin—urinary bladder cancer	0.000684	0.00391	CcSEcCtD
Indacaterol—Cough—Gemcitabine—urinary bladder cancer	0.000683	0.00391	CcSEcCtD
Indacaterol—Paraesthesia—Thiotepa—urinary bladder cancer	0.000682	0.0039	CcSEcCtD
Indacaterol—UGT1A1—Phase II conjugation—HPGDS—urinary bladder cancer	0.000681	0.00818	CbGpPWpGaD
Indacaterol—Anaemia—Cisplatin—urinary bladder cancer	0.000674	0.00386	CcSEcCtD
Indacaterol—Chest pain—Gemcitabine—urinary bladder cancer	0.000667	0.00381	CcSEcCtD
Indacaterol—Myalgia—Gemcitabine—urinary bladder cancer	0.000667	0.00381	CcSEcCtD
Indacaterol—Diabetes mellitus—Doxorubicin—urinary bladder cancer	0.000662	0.00379	CcSEcCtD
Indacaterol—Unspecified disorder of skin and subcutaneous tissue—Gemcitabine—urinary bladder cancer	0.000662	0.00379	CcSEcCtD
Indacaterol—UGT1A1—Phase II conjugation—GSTT1—urinary bladder cancer	0.00066	0.00793	CbGpPWpGaD
Indacaterol—Gastrointestinal disorder—Thiotepa—urinary bladder cancer	0.000656	0.00375	CcSEcCtD
Indacaterol—Chest pain—Fluorouracil—urinary bladder cancer	0.000655	0.00375	CcSEcCtD
Indacaterol—Myalgia—Fluorouracil—urinary bladder cancer	0.000655	0.00375	CcSEcCtD
Indacaterol—CYP3A4—female reproductive system—urinary bladder cancer	0.000652	0.0219	CbGeAlD
Indacaterol—ABCB1—Constitutive Androstane Receptor Pathway—SMC1A—urinary bladder cancer	0.000644	0.00774	CbGpPWpGaD
Indacaterol—Muscle spasms—Etoposide—urinary bladder cancer	0.000643	0.00368	CcSEcCtD
Indacaterol—Infection—Gemcitabine—urinary bladder cancer	0.000635	0.00363	CcSEcCtD
Indacaterol—Nervous system disorder—Gemcitabine—urinary bladder cancer	0.000627	0.00358	CcSEcCtD
Indacaterol—Infection—Fluorouracil—urinary bladder cancer	0.000624	0.00357	CcSEcCtD
Indacaterol—ABCB1—epithelium—urinary bladder cancer	0.000622	0.0208	CbGeAlD
Indacaterol—Myalgia—Cisplatin—urinary bladder cancer	0.000621	0.00355	CcSEcCtD
Indacaterol—Skin disorder—Gemcitabine—urinary bladder cancer	0.000621	0.00355	CcSEcCtD
Indacaterol—Anaemia—Etoposide—urinary bladder cancer	0.000618	0.00353	CcSEcCtD
Indacaterol—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—urinary bladder cancer	0.000617	0.00353	CcSEcCtD
Indacaterol—Nervous system disorder—Fluorouracil—urinary bladder cancer	0.000616	0.00352	CcSEcCtD
Indacaterol—Tachycardia—Fluorouracil—urinary bladder cancer	0.000613	0.00351	CcSEcCtD
Indacaterol—Vertigo—Etoposide—urinary bladder cancer	0.000601	0.00343	CcSEcCtD
Indacaterol—Infection—Cisplatin—urinary bladder cancer	0.000592	0.00338	CcSEcCtD
Indacaterol—Nervous system disorder—Cisplatin—urinary bladder cancer	0.000584	0.00334	CcSEcCtD
Indacaterol—Cough—Etoposide—urinary bladder cancer	0.000583	0.00334	CcSEcCtD
Indacaterol—Musculoskeletal discomfort—Gemcitabine—urinary bladder cancer	0.000582	0.00333	CcSEcCtD
Indacaterol—Tachycardia—Cisplatin—urinary bladder cancer	0.000581	0.00332	CcSEcCtD
Indacaterol—Skin disorder—Cisplatin—urinary bladder cancer	0.000579	0.00331	CcSEcCtD
Indacaterol—ABCB1—renal system—urinary bladder cancer	0.000577	0.0193	CbGeAlD
Indacaterol—Asthma—Methotrexate—urinary bladder cancer	0.000575	0.00329	CcSEcCtD
Indacaterol—Paraesthesia—Gemcitabine—urinary bladder cancer	0.000574	0.00328	CcSEcCtD
Indacaterol—Musculoskeletal discomfort—Fluorouracil—urinary bladder cancer	0.000572	0.00327	CcSEcCtD
Indacaterol—Dyspnoea—Gemcitabine—urinary bladder cancer	0.00057	0.00326	CcSEcCtD
Indacaterol—Chest pain—Etoposide—urinary bladder cancer	0.000569	0.00325	CcSEcCtD
Indacaterol—ABCB1—urethra—urinary bladder cancer	0.000566	0.019	CbGeAlD
Indacaterol—Hypokalaemia—Epirubicin—urinary bladder cancer	0.000566	0.00324	CcSEcCtD
Indacaterol—Unspecified disorder of skin and subcutaneous tissue—Etoposide—urinary bladder cancer	0.000565	0.00323	CcSEcCtD
Indacaterol—Paraesthesia—Fluorouracil—urinary bladder cancer	0.000564	0.00323	CcSEcCtD
Indacaterol—Dyspnoea—Fluorouracil—urinary bladder cancer	0.00056	0.0032	CcSEcCtD
Indacaterol—Hypersensitivity—Thiotepa—urinary bladder cancer	0.00056	0.0032	CcSEcCtD
Indacaterol—Nasopharyngitis—Epirubicin—urinary bladder cancer	0.000556	0.00318	CcSEcCtD
Indacaterol—CYP3A4—Estrogen metabolism—NQO1—urinary bladder cancer	0.000552	0.00663	CbGpPWpGaD
Indacaterol—Gastrointestinal disorder—Gemcitabine—urinary bladder cancer	0.000552	0.00315	CcSEcCtD
Indacaterol—Musculoskeletal discomfort—Cisplatin—urinary bladder cancer	0.000543	0.0031	CcSEcCtD
Indacaterol—Gastrointestinal disorder—Fluorouracil—urinary bladder cancer	0.000542	0.0031	CcSEcCtD
Indacaterol—Infection—Etoposide—urinary bladder cancer	0.000542	0.0031	CcSEcCtD
Indacaterol—Asthma—Epirubicin—urinary bladder cancer	0.000538	0.00308	CcSEcCtD
Indacaterol—Pruritus—Thiotepa—urinary bladder cancer	0.000537	0.00307	CcSEcCtD
Indacaterol—Paraesthesia—Cisplatin—urinary bladder cancer	0.000535	0.00306	CcSEcCtD
Indacaterol—Upper respiratory tract infection—Methotrexate—urinary bladder cancer	0.000534	0.00305	CcSEcCtD
Indacaterol—Tachycardia—Etoposide—urinary bladder cancer	0.000533	0.00304	CcSEcCtD
Indacaterol—Dyspnoea—Cisplatin—urinary bladder cancer	0.000531	0.00304	CcSEcCtD
Indacaterol—Skin disorder—Etoposide—urinary bladder cancer	0.00053	0.00303	CcSEcCtD
Indacaterol—Hypokalaemia—Doxorubicin—urinary bladder cancer	0.000524	0.003	CcSEcCtD
Indacaterol—Angina pectoris—Epirubicin—urinary bladder cancer	0.000524	0.003	CcSEcCtD
Indacaterol—Pneumonia—Methotrexate—urinary bladder cancer	0.000515	0.00295	CcSEcCtD
Indacaterol—Nasopharyngitis—Doxorubicin—urinary bladder cancer	0.000515	0.00294	CcSEcCtD
Indacaterol—Gastrointestinal disorder—Cisplatin—urinary bladder cancer	0.000514	0.00294	CcSEcCtD
Indacaterol—Infestation NOS—Methotrexate—urinary bladder cancer	0.000512	0.00293	CcSEcCtD
Indacaterol—Infestation—Methotrexate—urinary bladder cancer	0.000512	0.00293	CcSEcCtD
Indacaterol—Dizziness—Thiotepa—urinary bladder cancer	0.000502	0.00287	CcSEcCtD
Indacaterol—Upper respiratory tract infection—Epirubicin—urinary bladder cancer	0.0005	0.00286	CcSEcCtD
Indacaterol—UGT1A1—Biological oxidations—NAT2—urinary bladder cancer	0.000498	0.00599	CbGpPWpGaD
Indacaterol—Asthma—Doxorubicin—urinary bladder cancer	0.000498	0.00285	CcSEcCtD
Indacaterol—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP4B1—urinary bladder cancer	0.000491	0.0059	CbGpPWpGaD
Indacaterol—UGT1A1—Metapathway biotransformation—NAT2—urinary bladder cancer	0.000491	0.0059	CbGpPWpGaD
Indacaterol—Paraesthesia—Etoposide—urinary bladder cancer	0.00049	0.0028	CcSEcCtD
Indacaterol—Dyspnoea—Etoposide—urinary bladder cancer	0.000486	0.00278	CcSEcCtD
Indacaterol—Hyperglycaemia—Epirubicin—urinary bladder cancer	0.000485	0.00277	CcSEcCtD
Indacaterol—CYP3A4—Oxidation by Cytochrome P450—CYP4B1—urinary bladder cancer	0.000485	0.00583	CbGpPWpGaD
Indacaterol—Angina pectoris—Doxorubicin—urinary bladder cancer	0.000485	0.00277	CcSEcCtD
Indacaterol—Pneumonia—Epirubicin—urinary bladder cancer	0.000482	0.00276	CcSEcCtD
Indacaterol—Infestation NOS—Epirubicin—urinary bladder cancer	0.00048	0.00274	CcSEcCtD
Indacaterol—Infestation—Epirubicin—urinary bladder cancer	0.00048	0.00274	CcSEcCtD
Indacaterol—Rash—Thiotepa—urinary bladder cancer	0.000479	0.00274	CcSEcCtD
Indacaterol—Dermatitis—Thiotepa—urinary bladder cancer	0.000478	0.00274	CcSEcCtD
Indacaterol—Headache—Thiotepa—urinary bladder cancer	0.000476	0.00272	CcSEcCtD
Indacaterol—Gastrointestinal disorder—Etoposide—urinary bladder cancer	0.000471	0.00269	CcSEcCtD
Indacaterol—Hypersensitivity—Fluorouracil—urinary bladder cancer	0.000463	0.00265	CcSEcCtD
Indacaterol—Upper respiratory tract infection—Doxorubicin—urinary bladder cancer	0.000463	0.00264	CcSEcCtD
Indacaterol—ABCB1—female reproductive system—urinary bladder cancer	0.000462	0.0155	CbGeAlD
Indacaterol—UGT1A1—Phase II conjugation—GSTP1—urinary bladder cancer	0.000458	0.0055	CbGpPWpGaD
Indacaterol—Pruritus—Gemcitabine—urinary bladder cancer	0.000452	0.00258	CcSEcCtD
Indacaterol—Nausea—Thiotepa—urinary bladder cancer	0.000451	0.00258	CcSEcCtD
Indacaterol—Sinusitis—Epirubicin—urinary bladder cancer	0.00045	0.00257	CcSEcCtD
Indacaterol—Hyperglycaemia—Doxorubicin—urinary bladder cancer	0.000449	0.00257	CcSEcCtD
Indacaterol—Pneumonia—Doxorubicin—urinary bladder cancer	0.000446	0.00255	CcSEcCtD
Indacaterol—Pruritus—Fluorouracil—urinary bladder cancer	0.000444	0.00254	CcSEcCtD
Indacaterol—Infestation—Doxorubicin—urinary bladder cancer	0.000444	0.00254	CcSEcCtD
Indacaterol—Infestation NOS—Doxorubicin—urinary bladder cancer	0.000444	0.00254	CcSEcCtD
Indacaterol—Hypersensitivity—Cisplatin—urinary bladder cancer	0.000439	0.00251	CcSEcCtD
Indacaterol—Cardiac disorder—Methotrexate—urinary bladder cancer	0.000427	0.00244	CcSEcCtD
Indacaterol—Oedema peripheral—Epirubicin—urinary bladder cancer	0.000424	0.00242	CcSEcCtD
Indacaterol—CYP3A4—Estrogen metabolism—GSTM1—urinary bladder cancer	0.000423	0.00508	CbGpPWpGaD
Indacaterol—Connective tissue disorder—Epirubicin—urinary bladder cancer	0.000423	0.00242	CcSEcCtD
Indacaterol—UGT1A1—Phase II conjugation—GSTM1—urinary bladder cancer	0.000421	0.00505	CbGpPWpGaD
Indacaterol—ABCB1—vagina—urinary bladder cancer	0.000418	0.014	CbGeAlD
Indacaterol—Sinusitis—Doxorubicin—urinary bladder cancer	0.000416	0.00238	CcSEcCtD
Indacaterol—Immune system disorder—Methotrexate—urinary bladder cancer	0.000416	0.00238	CcSEcCtD
Indacaterol—Dizziness—Fluorouracil—urinary bladder cancer	0.000415	0.00238	CcSEcCtD
Indacaterol—Mediastinal disorder—Methotrexate—urinary bladder cancer	0.000415	0.00237	CcSEcCtD
Indacaterol—ADRB2—Arf6 trafficking events—CDH1—urinary bladder cancer	0.00041	0.00492	CbGpPWpGaD
Indacaterol—Rash—Gemcitabine—urinary bladder cancer	0.000403	0.0023	CcSEcCtD
Indacaterol—Dermatitis—Gemcitabine—urinary bladder cancer	0.000403	0.0023	CcSEcCtD
Indacaterol—Hypersensitivity—Etoposide—urinary bladder cancer	0.000402	0.0023	CcSEcCtD
Indacaterol—Malnutrition—Methotrexate—urinary bladder cancer	0.0004	0.00229	CcSEcCtD
Indacaterol—Headache—Gemcitabine—urinary bladder cancer	0.0004	0.00229	CcSEcCtD
Indacaterol—Cardiac disorder—Epirubicin—urinary bladder cancer	0.0004	0.00228	CcSEcCtD
Indacaterol—CYP3A4—Phase 1 - Functionalization of compounds—CYP4B1—urinary bladder cancer	0.000398	0.00479	CbGpPWpGaD
Indacaterol—UGT1A1—Biological oxidations—HPGDS—urinary bladder cancer	0.000398	0.00479	CbGpPWpGaD
Indacaterol—CYP3A4—Constitutive Androstane Receptor Pathway—SMC1A—urinary bladder cancer	0.000397	0.00477	CbGpPWpGaD
Indacaterol—Rash—Fluorouracil—urinary bladder cancer	0.000396	0.00227	CcSEcCtD
Indacaterol—Dermatitis—Fluorouracil—urinary bladder cancer	0.000396	0.00226	CcSEcCtD
Indacaterol—Headache—Fluorouracil—urinary bladder cancer	0.000394	0.00225	CcSEcCtD
Indacaterol—Oedema peripheral—Doxorubicin—urinary bladder cancer	0.000392	0.00224	CcSEcCtD
Indacaterol—Connective tissue disorder—Doxorubicin—urinary bladder cancer	0.000391	0.00224	CcSEcCtD
Indacaterol—Immune system disorder—Epirubicin—urinary bladder cancer	0.000389	0.00222	CcSEcCtD
Indacaterol—Mediastinal disorder—Epirubicin—urinary bladder cancer	0.000388	0.00222	CcSEcCtD
Indacaterol—UGT1A1—Biological oxidations—GSTT1—urinary bladder cancer	0.000386	0.00464	CbGpPWpGaD
Indacaterol—Pruritus—Etoposide—urinary bladder cancer	0.000386	0.00221	CcSEcCtD
Indacaterol—Nausea—Gemcitabine—urinary bladder cancer	0.00038	0.00217	CcSEcCtD
Indacaterol—Rash—Cisplatin—urinary bladder cancer	0.000376	0.00215	CcSEcCtD
Indacaterol—Dermatitis—Cisplatin—urinary bladder cancer	0.000375	0.00215	CcSEcCtD
Indacaterol—Malnutrition—Epirubicin—urinary bladder cancer	0.000375	0.00214	CcSEcCtD
Indacaterol—Nausea—Fluorouracil—urinary bladder cancer	0.000373	0.00213	CcSEcCtD
Indacaterol—Anaemia—Methotrexate—urinary bladder cancer	0.00037	0.00212	CcSEcCtD
Indacaterol—Cardiac disorder—Doxorubicin—urinary bladder cancer	0.00037	0.00211	CcSEcCtD
Indacaterol—UGT1A1—Aryl Hydrocarbon Receptor Pathway—IL2—urinary bladder cancer	0.000369	0.00444	CbGpPWpGaD
Indacaterol—UGT1A1—NRF2 pathway—NQO1—urinary bladder cancer	0.000366	0.0044	CbGpPWpGaD
Indacaterol—Dizziness—Etoposide—urinary bladder cancer	0.000361	0.00206	CcSEcCtD
Indacaterol—Muscle spasms—Epirubicin—urinary bladder cancer	0.00036	0.00206	CcSEcCtD
Indacaterol—Immune system disorder—Doxorubicin—urinary bladder cancer	0.00036	0.00206	CcSEcCtD
Indacaterol—Vertigo—Methotrexate—urinary bladder cancer	0.00036	0.00206	CcSEcCtD
Indacaterol—Mediastinal disorder—Doxorubicin—urinary bladder cancer	0.000359	0.00205	CcSEcCtD
Indacaterol—ABCB1—HIF-1-alpha transcription factor network—TFRC—urinary bladder cancer	0.000357	0.00429	CbGpPWpGaD
Indacaterol—Nausea—Cisplatin—urinary bladder cancer	0.000354	0.00202	CcSEcCtD
Indacaterol—Cough—Methotrexate—urinary bladder cancer	0.000349	0.002	CcSEcCtD
Indacaterol—Malnutrition—Doxorubicin—urinary bladder cancer	0.000347	0.00198	CcSEcCtD
Indacaterol—Anaemia—Epirubicin—urinary bladder cancer	0.000346	0.00198	CcSEcCtD
Indacaterol—ADRB2—Arf6 signaling events—SRC—urinary bladder cancer	0.000346	0.00416	CbGpPWpGaD
Indacaterol—Rash—Etoposide—urinary bladder cancer	0.000344	0.00197	CcSEcCtD
Indacaterol—Dermatitis—Etoposide—urinary bladder cancer	0.000344	0.00197	CcSEcCtD
Indacaterol—Headache—Etoposide—urinary bladder cancer	0.000342	0.00195	CcSEcCtD
Indacaterol—Chest pain—Methotrexate—urinary bladder cancer	0.000341	0.00195	CcSEcCtD
Indacaterol—Myalgia—Methotrexate—urinary bladder cancer	0.000341	0.00195	CcSEcCtD
Indacaterol—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	0.000339	0.00194	CcSEcCtD
Indacaterol—Vertigo—Epirubicin—urinary bladder cancer	0.000337	0.00193	CcSEcCtD
Indacaterol—Muscle spasms—Doxorubicin—urinary bladder cancer	0.000333	0.00191	CcSEcCtD
Indacaterol—UGT1A1—Aryl Hydrocarbon Receptor Pathway—EP300—urinary bladder cancer	0.000331	0.00398	CbGpPWpGaD
Indacaterol—Palpitations—Epirubicin—urinary bladder cancer	0.000331	0.00189	CcSEcCtD
Indacaterol—Cough—Epirubicin—urinary bladder cancer	0.000327	0.00187	CcSEcCtD
Indacaterol—Infection—Methotrexate—urinary bladder cancer	0.000325	0.00186	CcSEcCtD
Indacaterol—Nausea—Etoposide—urinary bladder cancer	0.000324	0.00185	CcSEcCtD
Indacaterol—UGT1A1—Aryl Hydrocarbon Receptor Pathway—SRC—urinary bladder cancer	0.000322	0.00387	CbGpPWpGaD
Indacaterol—Nervous system disorder—Methotrexate—urinary bladder cancer	0.000321	0.00183	CcSEcCtD
Indacaterol—Anaemia—Doxorubicin—urinary bladder cancer	0.00032	0.00183	CcSEcCtD
Indacaterol—Chest pain—Epirubicin—urinary bladder cancer	0.000319	0.00182	CcSEcCtD
Indacaterol—Myalgia—Epirubicin—urinary bladder cancer	0.000319	0.00182	CcSEcCtD
Indacaterol—Skin disorder—Methotrexate—urinary bladder cancer	0.000317	0.00182	CcSEcCtD
Indacaterol—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	0.000317	0.00181	CcSEcCtD
Indacaterol—Dry mouth—Epirubicin—urinary bladder cancer	0.000312	0.00178	CcSEcCtD
Indacaterol—Vertigo—Doxorubicin—urinary bladder cancer	0.000312	0.00178	CcSEcCtD
Indacaterol—Palpitations—Doxorubicin—urinary bladder cancer	0.000306	0.00175	CcSEcCtD
Indacaterol—UGT1A1—NRF2 pathway—GSTP1—urinary bladder cancer	0.000305	0.00367	CbGpPWpGaD
Indacaterol—Infection—Epirubicin—urinary bladder cancer	0.000304	0.00174	CcSEcCtD
Indacaterol—ADRB2—Arf6 signaling events—EGFR—urinary bladder cancer	0.000303	0.00365	CbGpPWpGaD
Indacaterol—Cough—Doxorubicin—urinary bladder cancer	0.000303	0.00173	CcSEcCtD
Indacaterol—Nervous system disorder—Epirubicin—urinary bladder cancer	0.0003	0.00172	CcSEcCtD
Indacaterol—Tachycardia—Epirubicin—urinary bladder cancer	0.000299	0.00171	CcSEcCtD
Indacaterol—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	0.000298	0.0017	CcSEcCtD
Indacaterol—Skin disorder—Epirubicin—urinary bladder cancer	0.000297	0.0017	CcSEcCtD
Indacaterol—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—urinary bladder cancer	0.000296	0.00356	CbGpPWpGaD
Indacaterol—Chest pain—Doxorubicin—urinary bladder cancer	0.000295	0.00169	CcSEcCtD
Indacaterol—Myalgia—Doxorubicin—urinary bladder cancer	0.000295	0.00169	CcSEcCtD
Indacaterol—Paraesthesia—Methotrexate—urinary bladder cancer	0.000293	0.00168	CcSEcCtD
Indacaterol—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	0.000293	0.00168	CcSEcCtD
Indacaterol—Dyspnoea—Methotrexate—urinary bladder cancer	0.000291	0.00167	CcSEcCtD
Indacaterol—Dry mouth—Doxorubicin—urinary bladder cancer	0.000289	0.00165	CcSEcCtD
Indacaterol—UGT1A1—Aryl Hydrocarbon Receptor Pathway—EGFR—urinary bladder cancer	0.000282	0.00339	CbGpPWpGaD
Indacaterol—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	0.000282	0.00161	CcSEcCtD
Indacaterol—Infection—Doxorubicin—urinary bladder cancer	0.000281	0.00161	CcSEcCtD
Indacaterol—UGT1A1—NRF2 pathway—GSTM1—urinary bladder cancer	0.000281	0.00337	CbGpPWpGaD
Indacaterol—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	0.000279	0.00159	CcSEcCtD
Indacaterol—Nervous system disorder—Doxorubicin—urinary bladder cancer	0.000278	0.00159	CcSEcCtD
Indacaterol—Tachycardia—Doxorubicin—urinary bladder cancer	0.000276	0.00158	CcSEcCtD
Indacaterol—Skin disorder—Doxorubicin—urinary bladder cancer	0.000275	0.00157	CcSEcCtD
Indacaterol—Paraesthesia—Epirubicin—urinary bladder cancer	0.000275	0.00157	CcSEcCtD
Indacaterol—Dyspnoea—Epirubicin—urinary bladder cancer	0.000273	0.00156	CcSEcCtD
Indacaterol—CYP3A4—Biological oxidations—GSTZ1—urinary bladder cancer	0.000271	0.00326	CbGpPWpGaD
Indacaterol—ABCB1—lymph node—urinary bladder cancer	0.00027	0.00905	CbGeAlD
Indacaterol—UGT1A1—Aryl Hydrocarbon Receptor Pathway—TNF—urinary bladder cancer	0.000269	0.00323	CbGpPWpGaD
Indacaterol—UGT1A1—Biological oxidations—GSTP1—urinary bladder cancer	0.000268	0.00322	CbGpPWpGaD
Indacaterol—CYP3A4—Metapathway biotransformation—GSTZ1—urinary bladder cancer	0.000267	0.00321	CbGpPWpGaD
Indacaterol—UGT1A1—Metapathway biotransformation—GSTP1—urinary bladder cancer	0.000264	0.00317	CbGpPWpGaD
Indacaterol—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	0.000264	0.00151	CcSEcCtD
Indacaterol—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	0.000258	0.00147	CcSEcCtD
Indacaterol—CYP3A4—Biological oxidations—GSTO2—urinary bladder cancer	0.000257	0.00309	CbGpPWpGaD
Indacaterol—CYP3A4—Biological oxidations—NAT1—urinary bladder cancer	0.000257	0.00309	CbGpPWpGaD
Indacaterol—Paraesthesia—Doxorubicin—urinary bladder cancer	0.000254	0.00145	CcSEcCtD
Indacaterol—CYP3A4—Metapathway biotransformation—GSTO2—urinary bladder cancer	0.000253	0.00305	CbGpPWpGaD
Indacaterol—Dyspnoea—Doxorubicin—urinary bladder cancer	0.000252	0.00144	CcSEcCtD
Indacaterol—UGT1A1—Biological oxidations—GSTM1—urinary bladder cancer	0.000246	0.00296	CbGpPWpGaD
Indacaterol—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	0.000244	0.0014	CcSEcCtD
Indacaterol—UGT1A1—Metapathway biotransformation—GSTM1—urinary bladder cancer	0.000243	0.00292	CbGpPWpGaD
Indacaterol—Hypersensitivity—Methotrexate—urinary bladder cancer	0.000241	0.00138	CcSEcCtD
Indacaterol—CYP3A4—Biological oxidations—UGT2B7—urinary bladder cancer	0.000235	0.00282	CbGpPWpGaD
Indacaterol—CYP3A4—Metapathway biotransformation—UGT2B7—urinary bladder cancer	0.000232	0.00279	CbGpPWpGaD
Indacaterol—Pruritus—Methotrexate—urinary bladder cancer	0.000231	0.00132	CcSEcCtD
Indacaterol—Hypersensitivity—Epirubicin—urinary bladder cancer	0.000225	0.00129	CcSEcCtD
Indacaterol—ABCB1—Integrated Pancreatic Cancer Pathway—LIG1—urinary bladder cancer	0.00022	0.00265	CbGpPWpGaD
Indacaterol—Pruritus—Epirubicin—urinary bladder cancer	0.000216	0.00124	CcSEcCtD
Indacaterol—Dizziness—Methotrexate—urinary bladder cancer	0.000216	0.00124	CcSEcCtD
Indacaterol—ABCB1—HIF-1-alpha transcription factor network—TERT—urinary bladder cancer	0.000214	0.00257	CbGpPWpGaD
Indacaterol—CYP3A4—Biological oxidations—CYP4B1—urinary bladder cancer	0.000212	0.00254	CbGpPWpGaD
Indacaterol—CYP3A4—Metapathway biotransformation—CYP4B1—urinary bladder cancer	0.000209	0.00251	CbGpPWpGaD
Indacaterol—Hypersensitivity—Doxorubicin—urinary bladder cancer	0.000209	0.00119	CcSEcCtD
Indacaterol—Rash—Methotrexate—urinary bladder cancer	0.000206	0.00118	CcSEcCtD
Indacaterol—Dermatitis—Methotrexate—urinary bladder cancer	0.000206	0.00118	CcSEcCtD
Indacaterol—Headache—Methotrexate—urinary bladder cancer	0.000205	0.00117	CcSEcCtD
Indacaterol—Dizziness—Epirubicin—urinary bladder cancer	0.000202	0.00116	CcSEcCtD
Indacaterol—Pruritus—Doxorubicin—urinary bladder cancer	0.0002	0.00114	CcSEcCtD
Indacaterol—Nausea—Methotrexate—urinary bladder cancer	0.000194	0.00111	CcSEcCtD
Indacaterol—Rash—Epirubicin—urinary bladder cancer	0.000193	0.0011	CcSEcCtD
Indacaterol—Dermatitis—Epirubicin—urinary bladder cancer	0.000193	0.0011	CcSEcCtD
Indacaterol—Headache—Epirubicin—urinary bladder cancer	0.000192	0.0011	CcSEcCtD
Indacaterol—ABCB1—Allograft Rejection—FAS—urinary bladder cancer	0.000189	0.00227	CbGpPWpGaD
Indacaterol—Dizziness—Doxorubicin—urinary bladder cancer	0.000187	0.00107	CcSEcCtD
Indacaterol—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—urinary bladder cancer	0.000182	0.00219	CbGpPWpGaD
Indacaterol—Nausea—Epirubicin—urinary bladder cancer	0.000182	0.00104	CcSEcCtD
Indacaterol—Rash—Doxorubicin—urinary bladder cancer	0.000178	0.00102	CcSEcCtD
Indacaterol—Dermatitis—Doxorubicin—urinary bladder cancer	0.000178	0.00102	CcSEcCtD
Indacaterol—Headache—Doxorubicin—urinary bladder cancer	0.000177	0.00101	CcSEcCtD
Indacaterol—Nausea—Doxorubicin—urinary bladder cancer	0.000168	0.000961	CcSEcCtD
Indacaterol—ABCB1—Integrated Pancreatic Cancer Pathway—HPGDS—urinary bladder cancer	0.000168	0.00202	CbGpPWpGaD
Indacaterol—ABCB1—HIF-1-alpha transcription factor network—CREBBP—urinary bladder cancer	0.000167	0.00201	CbGpPWpGaD
Indacaterol—ABCB1—Integrated Pancreatic Cancer Pathway—IGFBP3—urinary bladder cancer	0.000167	0.00201	CbGpPWpGaD
Indacaterol—UGT1A1—Metabolism—GSTZ1—urinary bladder cancer	0.000164	0.00197	CbGpPWpGaD
Indacaterol—UGT1A1—Metabolism—GSTO2—urinary bladder cancer	0.000155	0.00187	CbGpPWpGaD
Indacaterol—UGT1A1—Metabolism—NAT1—urinary bladder cancer	0.000155	0.00187	CbGpPWpGaD
Indacaterol—ABCB1—Transmembrane transport of small molecules—SLC14A2—urinary bladder cancer	0.000152	0.00183	CbGpPWpGaD
Indacaterol—UGT1A1—Metabolism—UGT2B7—urinary bladder cancer	0.000142	0.00171	CbGpPWpGaD
Indacaterol—CYP3A4—Biological oxidations—NAT2—urinary bladder cancer	0.000141	0.00169	CbGpPWpGaD
Indacaterol—CYP3A4—Metapathway biotransformation—NAT2—urinary bladder cancer	0.000139	0.00167	CbGpPWpGaD
Indacaterol—ABCB1—Integrated Pancreatic Cancer Pathway—ESR2—urinary bladder cancer	0.000134	0.00162	CbGpPWpGaD
Indacaterol—UGT1A1—Metabolism—CYP4B1—urinary bladder cancer	0.000128	0.00154	CbGpPWpGaD
Indacaterol—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—urinary bladder cancer	0.000126	0.00151	CbGpPWpGaD
Indacaterol—UGT1A1—Metabolism—SLC19A1—urinary bladder cancer	0.000121	0.00145	CbGpPWpGaD
Indacaterol—UGT1A1—Metabolism—PRSS3—urinary bladder cancer	0.000118	0.00142	CbGpPWpGaD
Indacaterol—ABCB1—Allograft Rejection—CXCL8—urinary bladder cancer	0.000115	0.00138	CbGpPWpGaD
Indacaterol—ABCB1—HIF-1-alpha transcription factor network—EP300—urinary bladder cancer	0.000114	0.00137	CbGpPWpGaD
Indacaterol—CYP3A4—Biological oxidations—HPGDS—urinary bladder cancer	0.000113	0.00135	CbGpPWpGaD
Indacaterol—ABCB1—Transmembrane transport of small molecules—AQP3—urinary bladder cancer	0.00011	0.00132	CbGpPWpGaD
Indacaterol—ABCB1—Allograft Rejection—IL2—urinary bladder cancer	0.00011	0.00132	CbGpPWpGaD
Indacaterol—CYP3A4—Biological oxidations—GSTT1—urinary bladder cancer	0.000109	0.00131	CbGpPWpGaD
Indacaterol—ABCB1—Integrated Pancreatic Cancer Pathway—CCNE1—urinary bladder cancer	0.000107	0.00128	CbGpPWpGaD
Indacaterol—ABCB1—Integrated Pancreatic Cancer Pathway—TYMS—urinary bladder cancer	0.000105	0.00126	CbGpPWpGaD
Indacaterol—UGT1A1—Metabolism—TYMP—urinary bladder cancer	9.42e-05	0.00113	CbGpPWpGaD
Indacaterol—ABCB1—Integrated Pancreatic Cancer Pathway—FAS—urinary bladder cancer	9.31e-05	0.00112	CbGpPWpGaD
Indacaterol—ABCB1—Transmembrane transport of small molecules—TRPV1—urinary bladder cancer	8.98e-05	0.00108	CbGpPWpGaD
Indacaterol—UGT1A1—Metabolism—NAT2—urinary bladder cancer	8.52e-05	0.00102	CbGpPWpGaD
Indacaterol—ADRB1—Signaling Pathways—HDAC4—urinary bladder cancer	8.3e-05	0.000997	CbGpPWpGaD
Indacaterol—ABCB1—Integrated Pancreatic Cancer Pathway—ATM—urinary bladder cancer	8.22e-05	0.000988	CbGpPWpGaD
Indacaterol—ABCB1—Integrated Pancreatic Cancer Pathway—CDK4—urinary bladder cancer	8.19e-05	0.000984	CbGpPWpGaD
Indacaterol—ABCB1—Integrated Pancreatic Cancer Pathway—ESR1—urinary bladder cancer	8.15e-05	0.00098	CbGpPWpGaD
Indacaterol—ADRB2—Signaling Pathways—HDAC4—urinary bladder cancer	8.11e-05	0.000975	CbGpPWpGaD
Indacaterol—ABCB1—Allograft Rejection—TNF—urinary bladder cancer	8.01e-05	0.000962	CbGpPWpGaD
Indacaterol—CYP3A4—Biological oxidations—GSTP1—urinary bladder cancer	7.57e-05	0.000909	CbGpPWpGaD
Indacaterol—ABCB1—Metabolism—GSTZ1—urinary bladder cancer	7.52e-05	0.000904	CbGpPWpGaD
Indacaterol—CYP3A4—Metapathway biotransformation—GSTP1—urinary bladder cancer	7.46e-05	0.000897	CbGpPWpGaD
Indacaterol—UGT1A1—Metabolism—RRM2—urinary bladder cancer	7.35e-05	0.000884	CbGpPWpGaD
Indacaterol—ADRB1—Class A/1 (Rhodopsin-like receptors)—CXCL8—urinary bladder cancer	7.35e-05	0.000884	CbGpPWpGaD
Indacaterol—ADRB2—Class A/1 (Rhodopsin-like receptors)—CXCL8—urinary bladder cancer	7.19e-05	0.000864	CbGpPWpGaD
Indacaterol—ABCB1—Integrated Pancreatic Cancer Pathway—CREBBP—urinary bladder cancer	7.15e-05	0.000859	CbGpPWpGaD
Indacaterol—ABCB1—Metabolism—GSTO2—urinary bladder cancer	7.13e-05	0.000857	CbGpPWpGaD
Indacaterol—ABCB1—Metabolism—NAT1—urinary bladder cancer	7.13e-05	0.000857	CbGpPWpGaD
Indacaterol—ABCB1—Integrated Pancreatic Cancer Pathway—IGF1—urinary bladder cancer	7.06e-05	0.000848	CbGpPWpGaD
Indacaterol—CYP3A4—Biological oxidations—GSTM1—urinary bladder cancer	6.95e-05	0.000836	CbGpPWpGaD
Indacaterol—ADRB1—Signaling Pathways—GLI1—urinary bladder cancer	6.95e-05	0.000835	CbGpPWpGaD
Indacaterol—CYP3A4—Metapathway biotransformation—GSTM1—urinary bladder cancer	6.86e-05	0.000824	CbGpPWpGaD
Indacaterol—UGT1A1—Metabolism—HPGDS—urinary bladder cancer	6.81e-05	0.000818	CbGpPWpGaD
Indacaterol—UGT1A1—Metabolism—ENO2—urinary bladder cancer	6.81e-05	0.000818	CbGpPWpGaD
Indacaterol—ADRB2—Signaling Pathways—GLI1—urinary bladder cancer	6.8e-05	0.000817	CbGpPWpGaD
Indacaterol—UGT1A1—Metabolism—GSTT1—urinary bladder cancer	6.61e-05	0.000794	CbGpPWpGaD
Indacaterol—ABCB1—Metabolism—UGT2B7—urinary bladder cancer	6.52e-05	0.000784	CbGpPWpGaD
Indacaterol—ABCB1—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	6.06e-05	0.000728	CbGpPWpGaD
Indacaterol—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—urinary bladder cancer	5.98e-05	0.000719	CbGpPWpGaD
Indacaterol—ABCB1—Metabolism—CYP4B1—urinary bladder cancer	5.87e-05	0.000706	CbGpPWpGaD
Indacaterol—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—urinary bladder cancer	5.85e-05	0.000703	CbGpPWpGaD
Indacaterol—ADRB1—GPCR ligand binding—CXCL8—urinary bladder cancer	5.6e-05	0.000673	CbGpPWpGaD
Indacaterol—ABCB1—Metabolism—SLC19A1—urinary bladder cancer	5.55e-05	0.000667	CbGpPWpGaD
Indacaterol—UGT1A1—Metabolism—NQO1—urinary bladder cancer	5.49e-05	0.00066	CbGpPWpGaD
Indacaterol—ADRB2—GPCR ligand binding—CXCL8—urinary bladder cancer	5.48e-05	0.000658	CbGpPWpGaD
Indacaterol—ABCB1—Metabolism—PRSS3—urinary bladder cancer	5.41e-05	0.00065	CbGpPWpGaD
Indacaterol—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—urinary bladder cancer	5.29e-05	0.000635	CbGpPWpGaD
Indacaterol—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1A—urinary bladder cancer	5.11e-05	0.000615	CbGpPWpGaD
Indacaterol—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—urinary bladder cancer	5.1e-05	0.000613	CbGpPWpGaD
Indacaterol—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—urinary bladder cancer	4.87e-05	0.000585	CbGpPWpGaD
Indacaterol—ADRB1—Signaling Pathways—RBX1—urinary bladder cancer	4.76e-05	0.000572	CbGpPWpGaD
Indacaterol—ABCB1—Integrated Pancreatic Cancer Pathway—SRC—urinary bladder cancer	4.73e-05	0.000569	CbGpPWpGaD
Indacaterol—ADRB2—Signaling Pathways—RBX1—urinary bladder cancer	4.66e-05	0.00056	CbGpPWpGaD
Indacaterol—CYP3A4—Metabolism—GSTZ1—urinary bladder cancer	4.64e-05	0.000557	CbGpPWpGaD
Indacaterol—UGT1A1—Metabolism—GSTP1—urinary bladder cancer	4.58e-05	0.00055	CbGpPWpGaD
Indacaterol—ADRB1—Signaling Pathways—TSC1—urinary bladder cancer	4.48e-05	0.000538	CbGpPWpGaD
Indacaterol—CYP3A4—Metabolism—GSTO2—urinary bladder cancer	4.39e-05	0.000528	CbGpPWpGaD
Indacaterol—CYP3A4—Metabolism—NAT1—urinary bladder cancer	4.39e-05	0.000528	CbGpPWpGaD
Indacaterol—ADRB2—Signaling Pathways—TSC1—urinary bladder cancer	4.38e-05	0.000526	CbGpPWpGaD
Indacaterol—ABCB1—Metabolism—TYMP—urinary bladder cancer	4.32e-05	0.000519	CbGpPWpGaD
Indacaterol—ADRB1—Signaling Pathways—JAG1—urinary bladder cancer	4.26e-05	0.000512	CbGpPWpGaD
Indacaterol—UGT1A1—Metabolism—TYMS—urinary bladder cancer	4.26e-05	0.000511	CbGpPWpGaD
Indacaterol—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—urinary bladder cancer	4.24e-05	0.00051	CbGpPWpGaD
Indacaterol—UGT1A1—Metabolism—NCOR1—urinary bladder cancer	4.21e-05	0.000506	CbGpPWpGaD
Indacaterol—UGT1A1—Metabolism—GSTM1—urinary bladder cancer	4.21e-05	0.000506	CbGpPWpGaD
Indacaterol—ADRB2—Signaling Pathways—JAG1—urinary bladder cancer	4.17e-05	0.000501	CbGpPWpGaD
Indacaterol—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—urinary bladder cancer	4.15e-05	0.000498	CbGpPWpGaD
Indacaterol—UGT1A1—Metabolism—GPX1—urinary bladder cancer	4.03e-05	0.000484	CbGpPWpGaD
Indacaterol—CYP3A4—Metabolism—UGT2B7—urinary bladder cancer	4.02e-05	0.000483	CbGpPWpGaD
Indacaterol—UGT1A1—Metabolism—ERCC2—urinary bladder cancer	3.96e-05	0.000475	CbGpPWpGaD
Indacaterol—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—urinary bladder cancer	3.95e-05	0.000475	CbGpPWpGaD
Indacaterol—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—urinary bladder cancer	3.92e-05	0.000471	CbGpPWpGaD
Indacaterol—ABCB1—Metabolism—NAT2—urinary bladder cancer	3.91e-05	0.00047	CbGpPWpGaD
Indacaterol—UGT1A1—Metabolism—MTHFR—urinary bladder cancer	3.72e-05	0.000447	CbGpPWpGaD
Indacaterol—CYP3A4—Metabolism—CYP4B1—urinary bladder cancer	3.62e-05	0.000435	CbGpPWpGaD
Indacaterol—ADRB1—GPCR downstream signaling—RHOA—urinary bladder cancer	3.6e-05	0.000433	CbGpPWpGaD
Indacaterol—ADRB2—GPCR downstream signaling—RHOA—urinary bladder cancer	3.53e-05	0.000424	CbGpPWpGaD
Indacaterol—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—urinary bladder cancer	3.48e-05	0.000418	CbGpPWpGaD
Indacaterol—ADRB1—Signaling Pathways—S100B—urinary bladder cancer	3.45e-05	0.000415	CbGpPWpGaD
Indacaterol—CYP3A4—Metabolism—SLC19A1—urinary bladder cancer	3.42e-05	0.000411	CbGpPWpGaD
Indacaterol—ADRB2—Signaling Pathways—S100B—urinary bladder cancer	3.38e-05	0.000406	CbGpPWpGaD
Indacaterol—ABCB1—Metabolism—RRM2—urinary bladder cancer	3.37e-05	0.000405	CbGpPWpGaD
Indacaterol—CYP3A4—Metabolism—PRSS3—urinary bladder cancer	3.33e-05	0.0004	CbGpPWpGaD
Indacaterol—ADRB1—Signaling by GPCR—RHOA—urinary bladder cancer	3.27e-05	0.000393	CbGpPWpGaD
Indacaterol—ADRB2—Signaling by GPCR—RHOA—urinary bladder cancer	3.2e-05	0.000385	CbGpPWpGaD
Indacaterol—ADRB1—GPCR downstream signaling—CXCL8—urinary bladder cancer	3.16e-05	0.00038	CbGpPWpGaD
Indacaterol—ABCB1—Metabolism—HPGDS—urinary bladder cancer	3.12e-05	0.000375	CbGpPWpGaD
Indacaterol—ABCB1—Metabolism—ENO2—urinary bladder cancer	3.12e-05	0.000375	CbGpPWpGaD
Indacaterol—ADRB1—Signaling Pathways—NCOR1—urinary bladder cancer	3.1e-05	0.000373	CbGpPWpGaD
Indacaterol—ADRB2—GPCR downstream signaling—CXCL8—urinary bladder cancer	3.1e-05	0.000372	CbGpPWpGaD
Indacaterol—ADRB2—Signaling Pathways—NCOR1—urinary bladder cancer	3.04e-05	0.000365	CbGpPWpGaD
Indacaterol—ABCB1—Metabolism—GSTT1—urinary bladder cancer	3.03e-05	0.000364	CbGpPWpGaD
Indacaterol—ADRB1—GPCR downstream signaling—IL2—urinary bladder cancer	3.02e-05	0.000363	CbGpPWpGaD
Indacaterol—UGT1A1—Metabolism—PPARG—urinary bladder cancer	3.02e-05	0.000362	CbGpPWpGaD
Indacaterol—ADRB2—GPCR downstream signaling—IL2—urinary bladder cancer	2.96e-05	0.000355	CbGpPWpGaD
Indacaterol—UGT1A1—Metabolism—CREBBP—urinary bladder cancer	2.9e-05	0.000348	CbGpPWpGaD
Indacaterol—ADRB1—Signaling by GPCR—CXCL8—urinary bladder cancer	2.87e-05	0.000345	CbGpPWpGaD
Indacaterol—ABCB1—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	2.84e-05	0.000341	CbGpPWpGaD
Indacaterol—ADRB2—Signaling by GPCR—CXCL8—urinary bladder cancer	2.81e-05	0.000338	CbGpPWpGaD
Indacaterol—ADRB1—Signaling by GPCR—IL2—urinary bladder cancer	2.75e-05	0.00033	CbGpPWpGaD
Indacaterol—ADRB1—Signaling Pathways—TERT—urinary bladder cancer	2.74e-05	0.000329	CbGpPWpGaD
Indacaterol—ADRB2—Signaling by GPCR—IL2—urinary bladder cancer	2.69e-05	0.000323	CbGpPWpGaD
Indacaterol—ADRB2—Signaling Pathways—TERT—urinary bladder cancer	2.68e-05	0.000322	CbGpPWpGaD
Indacaterol—CYP3A4—Metabolism—TYMP—urinary bladder cancer	2.66e-05	0.00032	CbGpPWpGaD
Indacaterol—ABCB1—Metabolism—NQO1—urinary bladder cancer	2.52e-05	0.000303	CbGpPWpGaD
Indacaterol—ADRB1—Signaling Pathways—FGFR3—urinary bladder cancer	2.51e-05	0.000302	CbGpPWpGaD
Indacaterol—ADRB2—Signaling Pathways—FGFR3—urinary bladder cancer	2.46e-05	0.000295	CbGpPWpGaD
Indacaterol—ADRB1—Signaling Pathways—ESR1—urinary bladder cancer	2.44e-05	0.000293	CbGpPWpGaD
Indacaterol—CYP3A4—Metabolism—NAT2—urinary bladder cancer	2.41e-05	0.000289	CbGpPWpGaD
Indacaterol—ADRB2—Signaling Pathways—ESR1—urinary bladder cancer	2.39e-05	0.000287	CbGpPWpGaD
Indacaterol—UGT1A1—Metabolism—PTGS2—urinary bladder cancer	2.37e-05	0.000285	CbGpPWpGaD
Indacaterol—ADRB1—Signaling Pathways—CREBBP—urinary bladder cancer	2.14e-05	0.000257	CbGpPWpGaD
Indacaterol—ADRB1—Signaling Pathways—IGF1—urinary bladder cancer	2.11e-05	0.000254	CbGpPWpGaD
Indacaterol—ABCB1—Metabolism—GSTP1—urinary bladder cancer	2.1e-05	0.000252	CbGpPWpGaD
Indacaterol—ADRB1—Signaling by GPCR—EGFR—urinary bladder cancer	2.1e-05	0.000252	CbGpPWpGaD
Indacaterol—ADRB2—Signaling Pathways—CREBBP—urinary bladder cancer	2.09e-05	0.000251	CbGpPWpGaD
Indacaterol—CYP3A4—Metabolism—RRM2—urinary bladder cancer	2.08e-05	0.00025	CbGpPWpGaD
Indacaterol—UGT1A1—Metabolism—PTEN—urinary bladder cancer	2.07e-05	0.000249	CbGpPWpGaD
Indacaterol—ADRB2—Signaling Pathways—IGF1—urinary bladder cancer	2.06e-05	0.000248	CbGpPWpGaD
Indacaterol—ADRB2—Signaling by GPCR—EGFR—urinary bladder cancer	2.05e-05	0.000247	CbGpPWpGaD
Indacaterol—ADRB1—Signaling by GPCR—KRAS—urinary bladder cancer	1.98e-05	0.000238	CbGpPWpGaD
Indacaterol—UGT1A1—Metabolism—EP300—urinary bladder cancer	1.97e-05	0.000237	CbGpPWpGaD
Indacaterol—ABCB1—Metabolism—TYMS—urinary bladder cancer	1.95e-05	0.000235	CbGpPWpGaD
Indacaterol—ADRB2—Signaling by GPCR—KRAS—urinary bladder cancer	1.94e-05	0.000233	CbGpPWpGaD
Indacaterol—ADRB1—Signaling Pathways—RHOA—urinary bladder cancer	1.93e-05	0.000232	CbGpPWpGaD
Indacaterol—ABCB1—Metabolism—NCOR1—urinary bladder cancer	1.93e-05	0.000232	CbGpPWpGaD
Indacaterol—ABCB1—Metabolism—GSTM1—urinary bladder cancer	1.93e-05	0.000232	CbGpPWpGaD
Indacaterol—CYP3A4—Metabolism—ENO2—urinary bladder cancer	1.93e-05	0.000231	CbGpPWpGaD
Indacaterol—CYP3A4—Metabolism—HPGDS—urinary bladder cancer	1.93e-05	0.000231	CbGpPWpGaD
Indacaterol—ADRB2—Signaling Pathways—RHOA—urinary bladder cancer	1.89e-05	0.000227	CbGpPWpGaD
Indacaterol—CYP3A4—Metabolism—GSTT1—urinary bladder cancer	1.87e-05	0.000224	CbGpPWpGaD
Indacaterol—ABCB1—Metabolism—GPX1—urinary bladder cancer	1.85e-05	0.000222	CbGpPWpGaD
Indacaterol—ABCB1—Metabolism—ERCC2—urinary bladder cancer	1.81e-05	0.000218	CbGpPWpGaD
Indacaterol—ADRB1—Signaling Pathways—ERBB2—urinary bladder cancer	1.79e-05	0.000215	CbGpPWpGaD
Indacaterol—ADRB2—Signaling Pathways—ERBB2—urinary bladder cancer	1.75e-05	0.00021	CbGpPWpGaD
Indacaterol—ABCB1—Metabolism—MTHFR—urinary bladder cancer	1.71e-05	0.000205	CbGpPWpGaD
Indacaterol—ADRB1—Signaling Pathways—CXCL8—urinary bladder cancer	1.7e-05	0.000204	CbGpPWpGaD
Indacaterol—ADRB1—Signaling by GPCR—HRAS—urinary bladder cancer	1.69e-05	0.000203	CbGpPWpGaD
Indacaterol—ADRB2—Signaling Pathways—CXCL8—urinary bladder cancer	1.66e-05	0.0002	CbGpPWpGaD
Indacaterol—ADRB2—Signaling by GPCR—HRAS—urinary bladder cancer	1.65e-05	0.000198	CbGpPWpGaD
Indacaterol—ADRB1—Signaling Pathways—IL2—urinary bladder cancer	1.62e-05	0.000195	CbGpPWpGaD
Indacaterol—ADRB2—Signaling Pathways—IL2—urinary bladder cancer	1.59e-05	0.000191	CbGpPWpGaD
Indacaterol—ADRB1—Signaling Pathways—CCND1—urinary bladder cancer	1.58e-05	0.00019	CbGpPWpGaD
Indacaterol—CYP3A4—Metabolism—NQO1—urinary bladder cancer	1.55e-05	0.000186	CbGpPWpGaD
Indacaterol—ADRB2—Signaling Pathways—CCND1—urinary bladder cancer	1.55e-05	0.000186	CbGpPWpGaD
Indacaterol—ADRB1—Signaling Pathways—MMP9—urinary bladder cancer	1.54e-05	0.000184	CbGpPWpGaD
Indacaterol—ADRB1—Signaling Pathways—CDKN1A—urinary bladder cancer	1.53e-05	0.000184	CbGpPWpGaD
Indacaterol—ADRB1—Signaling Pathways—PTEN—urinary bladder cancer	1.53e-05	0.000183	CbGpPWpGaD
Indacaterol—ADRB2—Signaling Pathways—MMP9—urinary bladder cancer	1.5e-05	0.00018	CbGpPWpGaD
Indacaterol—ADRB2—Signaling Pathways—CDKN1A—urinary bladder cancer	1.5e-05	0.00018	CbGpPWpGaD
Indacaterol—ADRB2—Signaling Pathways—PTEN—urinary bladder cancer	1.49e-05	0.000179	CbGpPWpGaD
Indacaterol—ADRB1—Signaling Pathways—EP300—urinary bladder cancer	1.46e-05	0.000175	CbGpPWpGaD
Indacaterol—ADRB2—Signaling Pathways—EP300—urinary bladder cancer	1.42e-05	0.000171	CbGpPWpGaD
Indacaterol—ADRB1—Signaling Pathways—SRC—urinary bladder cancer	1.42e-05	0.00017	CbGpPWpGaD
Indacaterol—ADRB2—Signaling Pathways—SRC—urinary bladder cancer	1.38e-05	0.000166	CbGpPWpGaD
Indacaterol—ABCB1—Metabolism—PPARG—urinary bladder cancer	1.38e-05	0.000166	CbGpPWpGaD
Indacaterol—ABCB1—Metabolism—CREBBP—urinary bladder cancer	1.33e-05	0.00016	CbGpPWpGaD
Indacaterol—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	1.29e-05	0.000155	CbGpPWpGaD
Indacaterol—ADRB1—Signaling Pathways—MYC—urinary bladder cancer	1.27e-05	0.000152	CbGpPWpGaD
Indacaterol—ADRB2—Signaling Pathways—MYC—urinary bladder cancer	1.24e-05	0.000149	CbGpPWpGaD
Indacaterol—ADRB1—Signaling Pathways—EGFR—urinary bladder cancer	1.24e-05	0.000149	CbGpPWpGaD
Indacaterol—ADRB2—Signaling Pathways—EGFR—urinary bladder cancer	1.21e-05	0.000146	CbGpPWpGaD
Indacaterol—CYP3A4—Metabolism—TYMS—urinary bladder cancer	1.2e-05	0.000145	CbGpPWpGaD
Indacaterol—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	1.19e-05	0.000143	CbGpPWpGaD
Indacaterol—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	1.19e-05	0.000143	CbGpPWpGaD
Indacaterol—ADRB1—Signaling Pathways—KRAS—urinary bladder cancer	1.17e-05	0.000141	CbGpPWpGaD
Indacaterol—ADRB2—Signaling Pathways—KRAS—urinary bladder cancer	1.15e-05	0.000138	CbGpPWpGaD
Indacaterol—CYP3A4—Metabolism—GPX1—urinary bladder cancer	1.14e-05	0.000137	CbGpPWpGaD
Indacaterol—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	1.12e-05	0.000134	CbGpPWpGaD
Indacaterol—ABCB1—Metabolism—PTGS2—urinary bladder cancer	1.09e-05	0.000131	CbGpPWpGaD
Indacaterol—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	1.05e-05	0.000126	CbGpPWpGaD
Indacaterol—ADRB1—Signaling Pathways—TP53—urinary bladder cancer	1.04e-05	0.000125	CbGpPWpGaD
Indacaterol—ADRB2—Signaling Pathways—TP53—urinary bladder cancer	1.02e-05	0.000122	CbGpPWpGaD
Indacaterol—ADRB1—Signaling Pathways—HRAS—urinary bladder cancer	9.96e-06	0.00012	CbGpPWpGaD
Indacaterol—ADRB2—Signaling Pathways—HRAS—urinary bladder cancer	9.75e-06	0.000117	CbGpPWpGaD
Indacaterol—ABCB1—Metabolism—PTEN—urinary bladder cancer	9.49e-06	0.000114	CbGpPWpGaD
Indacaterol—ABCB1—Metabolism—EP300—urinary bladder cancer	9.05e-06	0.000109	CbGpPWpGaD
Indacaterol—CYP3A4—Metabolism—PPARG—urinary bladder cancer	8.52e-06	0.000102	CbGpPWpGaD
Indacaterol—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	8.19e-06	9.84e-05	CbGpPWpGaD
Indacaterol—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	6.7e-06	8.06e-05	CbGpPWpGaD
Indacaterol—CYP3A4—Metabolism—PTEN—urinary bladder cancer	5.85e-06	7.03e-05	CbGpPWpGaD
Indacaterol—CYP3A4—Metabolism—EP300—urinary bladder cancer	5.58e-06	6.7e-05	CbGpPWpGaD
